课题基金 / 基金详情

The Impact of FUS-Mediated Brain Cancer Therapy on BBB Transport, Cytokines, and Immunocyte Trafficking

The Impact of FUS-Mediated Brain Cancer Therapy on BBB Transport, Cytokines, and Immunocyte Trafficking
FUS 介导的脑癌治疗对 BBB 运输、细胞因子和免疫细胞贩运的影响
批准号:
10356815
负责人:
Kim Butts-Pauly
金额:
$58.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-03-01 至 2024-02-29
关键词:

项目摘要

项目成果

Kim Butts-Pauly的其他基金

相似基金

相关文献

中文摘要
翻译
项目摘要 脑癌的存活率令人沮丧。胶质瘤切除后,复发发生在肿瘤细胞-- 在增强MRI上增强的区域周围有浸润性组织。以抗体为基础的治疗 脑癌是非常有希望的。然而,实现这些有希望的目标的一个剩余障碍 治疗方法是血脑屏障(BBB)。血脑屏障通常不包括0.4 kDa及以上的药物, 抗体大小为150 kDa。聚焦超声(FUS)将超声能量集中在一小块区域内。低 强度超声与静脉注射的微泡相互作用,打开血脑屏障。气泡振荡 对内皮细胞施加机械压力。这些压力振荡导致了 大分子通过各种机制通过血脑屏障的运输,包括通过细胞和 通过缝隙连接。在临床前研究中,FUS血脑屏障开放已被用来输送化疗药物。 药物、抗体、干细胞和靶向基因。为了将抗体最佳地传递到人脑,额外的 为了使血脑屏障开放安全、准确和完全可逆,迫切需要基于成像的工具。一个 FUS与免疫治疗方案相结合可能改变游戏规则的特征是MRgFUS 血脑屏障开放已被证明可上调多种促炎和抗炎细胞因子、趋化因子和 营养因子和细胞黏附分子在血脑屏障开放后5分钟至24小时。言下之意是 FUS BBB的开放可能不仅会影响药物的释放,而且还会增强 免疫细胞或增强免疫治疗药物的有效性。我们的目标是设计一个战略,以 将治疗提供与创造抗肿瘤微环境相结合。开发一种 了解微泡膨胀与血管塌陷、改变之间的复杂关系 渗透性、细胞因子谱的改变以及由此导致的细胞迁移和微出血是必需的。我们 寻求将治疗药物的提供与免疫细胞的归巢结合在一起,以避免微型... 大出血。此外,我们希望用与临床相关的频率(220和650 kHz)来实现这一点。我们 对这些场景进行了建模,开发了参数集,通过实验进行了测试。我们的目标是评估这一点 在小动物模型和大动物模型中的响应以及在大动物模型中演示射束校准的方法 动物模型。我们的具体目标是:1)评估微泡振荡、细胞因子、 血脑屏障完整的正常小鼠的治疗传递、免疫细胞转运和微出血 创建安全增强递送的策略,同时产生潜在的抗肿瘤微环境 表型,2)评估EGFR抗体的治疗传递、免疫细胞转运和小鼠的存活 基于目标1中制定的策略的荷瘤胶质母细胞瘤,以及3)确定 在AIM 1的小鼠身上观察到的结果在一个大型动物模型中复制。
英文摘要
Project Abstract Brain cancer survival rates are dismal. After resection of glial tumors, recurrence occurs in the tumor-cell- infiltrated tissue surrounding the area that enhances on contrast enhanced MRI. Antibody-based treatments for brain cancer are extremely promising. However, a remaining obstacle to the delivery of these promising treatments is the blood-brain barrier (BBB). The BBB normally excludes drugs of size 0.4 kDa and higher, while antibodies are 150 kDa. Focused ultrasound (FUS) concentrates ultrasonic energy to a small area. Low intensity ultrasound interacts with intravenously injected microbubbles to open the BBB. Bubble oscillations exert mechanical pressure on endothelial cells. These pressure oscillations result in an increase in the transport of large molecules across the BBB via a variety of mechanisms including transport through cells and through gap junctions. In preclinical studies, FUS BBB opening has been used to deliver chemotherapeutic agents, antibodies, stem cells, and targeted genes. For optimal antibody delivery to the human brain, additional imaging-based tools are urgently needed to make BBB opening safe, accurate, and fully reversible. A potentially game changing characteristic of FUS in combination with immunotherapy protocols is that MRgFUS BBB opening has been shown to upregulate multiple pro- and anti- inflammatory cytokines, chemokines and trophic factors, and cell adhesion molecules from 5 minutes to 24 hours after BBB opening. The implication is that FUS BBB opening may have the potential to not just affect the drug delivery but also to enhance homing of immune cells or to potentiate the effectiveness of an immunotherapy drug. Our goal is to design a strategy to combine therapeutic delivery with the creation of an anti-tumor microenvironment. Developing an understanding of the complex relationship between microbubble expansion and collapse, changes in vascular permeability, changes in cytokine profiles and resulting cell trafficking and micro-hemorrhage is required. We seek to combine the delivery of therapeutics and the homing of immune cells in a regime that avoids micro- hemorrhage. Further, we wish to accomplish this with clinically-relevant frequencies (220 and 650 kHz). We have modeled these scenarios to develop a parameter set to test through experiment. We aim to evaluate this response in both small and large animal models and to demonstrate methods for beam calibration in the large animal model. Our Specific Aims are to: 1) assess the relationship of microbubble oscillation, cytokines, therapeutic delivery, immune cell trafficking and micro-hemorrhage in normal mice with an intact BBB and create a strategy for safely enhancing delivery while generating potentially an anti-tumor microenvironment phenotype, 2) assess therapeutic delivery of EGFR antibodies, immunocyte trafficking, and survival in mice bearing glioblastoma based on the strategy developed in Aim 1, and 3) Determine whether relationships observed in mice in Aim 1 are replicated in a large animal model.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Step 1 in Designing Appropriate Shams and Controls in Human TUS
  • 批准号:
    10735292
  • 项目类别:
  • 资助金额:
    $63.94万
  • 财政年份:
    2023
  • 负责人:
    Kim Butts-Pauly
  • 依托单位:
Stanford's Translational Biomedical Imaging Instrumentation (TBI2) Training Program
  • 批准号:
    10627475
  • 项目类别:
  • 资助金额:
    $10.92万
  • 财政年份:
    2023
  • 负责人:
    Kim Butts-Pauly
  • 依托单位:
Rapid brain-wide optogenetic screening with a noninvasive, dynamically programmable in vivo light source
  • 批准号:
    10401548
  • 项目类别:
  • 资助金额:
    $180.0万
  • 财政年份:
    2022
  • 负责人:
    Kim Butts-Pauly
  • 依托单位:
CRCNS: Crossbeam Transcranial Ultrasound Technology to Stimulate the Deep Brain
  • 批准号:
    10482358
  • 项目类别:
  • 资助金额:
    $15.94万
  • 财政年份:
    2021
  • 负责人:
    Kim Butts-Pauly
  • 依托单位:
海外基金